SEC Form 4 · accession 0001140361-15-024569

Emergent BioSolutions Inc. · EBS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Biodefense Divison

Period of report

Jun 15, 2015

Accepted (ET)

Jun 17, 2015 · 3:58 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jun 15, 2015	M	15,919	$14.67	A	57,363	D
Common Stock^F1,F2,F3	Jun 15, 2015	S	15,919	$31.502	D	41,444	D
Common Stock^F4	Jun 15, 2015	M	9,773	$15.83	A	51,217	D
Common Stock^F4,F2,F5	Jun 15, 2015	S	9,773	$31.665	D	41,444	D
Common Stock^F2,F6	Jun 15, 2015	S	10,606	$31.502	D	30,838	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option^F1,F7	$14.67	Jun 15, 2015	M	15,919	D	—	Mar 11, 2010	Common Stock	15,919	7,960	D
Stock Option^F4,F8	$15.83	Jun 15, 2015	M	9,773	D	—	Mar 12, 2019	Common Stock	9,773	0	D

F1Consists of an option granted under the company's stock incentive plan on March 12, 2013.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.
F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.055 to $31.77, inclusive.
F4Consists of an option granted under the company's stock incentive plan on March 13, 2012.
F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.66 to $31.72, inclusive.
F6The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.03 to $31.76, inclusive.
F7The option vested in three equal installments in March 2014, 2015 and 2016
F8The option vested in three equal installments in March 2013, 2014 and 2015.